Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CRVO CervoMed	$9.71 +3.2%	$7.60	$1.80 ▼ $20.63	$89.76M	-0.79	2.11 million shs	79,421 shs
IPA ImmunoPrecise Antibodies	$1.98 -2.2%	$1.41	$0.27 ▼ $2.41	$91.15M	0.49	4.17 million shs	318,470 shs
MIST Milestone Pharmaceuticals	$1.72 +3.3%	$1.71	$0.63 ▼ $2.75	$92.75M	0.52	1.75 million shs	908,624 shs
RLMD Relmada Therapeutics	$0.57 -3.6%	$0.65	$0.24 ▼ $3.98	$19.18M	0.66	1.18 million shs	153,789 shs

7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CRVO CervoMed	-1.05%	-6.47%	+31.47%	+12.98%	-22.51%
IPA ImmunoPrecise Antibodies	+6.32%	+11.60%	+36.49%	+306.44%	+240.07%
MIST Milestone Pharmaceuticals	+7.10%	+7.79%	+6.41%	+41.88%	+17.73%
RLMD Relmada Therapeutics	+4.42%	+3.34%	-3.61%	+36.74%	-74.43%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CRVO CervoMed	2.6007 of 5 stars	3.4	3.0	0.0	2.4	1.7	0.6
IPA ImmunoPrecise Antibodies	2.296 of 5 stars	3.5	3.0	0.0	2.8	0.0	0.6
MIST Milestone Pharmaceuticals	2.0399 of 5 stars	3.2	2.0	0.0	2.6	2.5	0.0
RLMD Relmada Therapeutics	4.5539 of 5 stars	3.1	5.0	4.4	1.6	4.2	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CRVO CervoMed	2.78	Moderate Buy	$21.43	120.80% Upside
IPA ImmunoPrecise Antibodies	3.00	Buy	$4.00	102.53% Upside
MIST Milestone Pharmaceuticals	2.40	Hold	$7.00	308.16% Upside
RLMD Relmada Therapeutics	2.25	Hold	$5.00	781.83% Upside

Current Analyst Ratings Breakdown

Latest RLMD, CRVO, MIST, and IPA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/12/2025	CRVO CervoMed	Roth Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Buy ➝ Buy	$20.00 ➝ $16.00
8/11/2025	CRVO CervoMed	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$10.00 ➝ $15.00
8/11/2025	CRVO CervoMed	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$15.00
7/29/2025	CRVO CervoMed	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$21.00 ➝ $27.00
7/25/2025	CRVO CervoMed	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00
6/11/2025	CRVO CervoMed	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00
6/5/2025	MIST Milestone Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Buy	$5.00
5/13/2025	CRVO CervoMed	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00 ➝ $10.00

(Data available from 8/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CRVO CervoMed	$9.74M	9.22	N/A	N/A	$3.61 per share	2.69
IPA ImmunoPrecise Antibodies	$17.59M	5.18	N/A	N/A	$0.37 per share	5.34
MIST Milestone Pharmaceuticals	$1M	91.68	N/A	N/A	$0.25 per share	6.86
RLMD Relmada Therapeutics	N/A	N/A	N/A	N/A	$0.48 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CRVO CervoMed	-$16.29M	-$2.61	N/A	N/A	N/A	-290.72%	-59.15%	-53.64%	N/A
IPA ImmunoPrecise Antibodies	-$21.69M	-$0.68	N/A	N/A	N/A	-122.10%	-40.62%	-22.19%	9/15/2025 (Estimated)
MIST Milestone Pharmaceuticals	-$41.52M	-$0.78	N/A	N/A	N/A	N/A	-329.85%	-67.20%	8/14/2025 (Estimated)
RLMD Relmada Therapeutics	-$79.98M	-$2.22	N/A	N/A	N/A	N/A	-223.17%	-180.41%	N/A

Latest RLMD, CRVO, MIST, and IPA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2025	Q2 2025	MIST Milestone Pharmaceuticals	-$0.18	-$0.20	-$0.02	-$0.20	N/A	N/A
8/8/2025	Q2 2025	CRVO CervoMed	-$0.57	-$0.70	-$0.13	-$0.70	$1.45 million	$1.76 million
8/7/2025	Q2 2025	RLMD Relmada Therapeutics	-$0.25	-$0.30	-$0.05	-$0.30	N/A	N/A
7/29/2025	Q4 2025	IPA ImmunoPrecise Antibodies	-$0.02	-$0.04	-$0.02	-$0.04	$7.89 million	$5.06 million
5/14/2025	Q1 2025	MIST Milestone Pharmaceuticals	-$0.19	-$0.31	-$0.12	-$0.31	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CRVO CervoMed	N/A	N/A	N/A	N/A	N/A
IPA ImmunoPrecise Antibodies	N/A	N/A	N/A	N/A	N/A
MIST Milestone Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
RLMD Relmada Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CRVO CervoMed	N/A	8.20	9.78
IPA ImmunoPrecise Antibodies	0.49	2.08	1.85
MIST Milestone Pharmaceuticals	4.06	4.67	4.67
RLMD Relmada Therapeutics	N/A	4.11	4.11

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CRVO CervoMed	25.15%
IPA ImmunoPrecise Antibodies	6.70%
MIST Milestone Pharmaceuticals	86.18%
RLMD Relmada Therapeutics	45.24%

Insider Ownership

Company	Insider Ownership
CRVO CervoMed	35.40%
IPA ImmunoPrecise Antibodies	6.83%
MIST Milestone Pharmaceuticals	19.50%
RLMD Relmada Therapeutics	20.70%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CRVO CervoMed	4	9.25 million	5.62 million	Not Optionable
IPA ImmunoPrecise Antibodies	80	46.15 million	43.00 million	Not Optionable
MIST Milestone Pharmaceuticals	30	53.46 million	43.04 million	Optionable
RLMD Relmada Therapeutics	10	33.19 million	26.32 million	Optionable

RLMD, CRVO, MIST, and IPA Headlines

Recent News About These Companies

Relmada Therapeutics, Inc. (NASDAQ:RLMD) Q2 2025 Earnings Call Transcript

August 12 at 8:58 AM | msn.com

Relmada Therapeutics Reports Promising Phase 2 Study Results

August 11 at 11:05 AM | theglobeandmail.com

Relmada Therapeutics (NASDAQ:RLMD) Upgraded to Hold at Wall Street Zen

August 9, 2025 | americanbankingnews.com

Relmada Therapeutics, Inc. (RLMD) Q2 2025 Earnings Call Transcript

August 8, 2025 | seekingalpha.com

Relmada Therapeutics to Report Second Quarter 2025 Financial Results on Thursday, August 7, 2025

July 31, 2025 | globenewswire.com

Relmada Therapeutics Appoints Renowned Urologic Oncologist, Yair Lotan, MD, to Chair the Clinical Advisory Board and Support Development of NDV-01

July 15, 2025 | finance.yahoo.com

Relmada Therapeutics Appoints Renowned Urologic Oncologist, Yair Lotan, MD, to Chair the Clinical Advisory Board and Support Development of NDV-01

July 15, 2025 | globenewswire.com

Relmada terminates license agreement for troubled phase 3 depression asset

July 11, 2025 | fiercebiotech.comF

DIMERx Appoints Biotech Leader Sergio Traversa, PharmD, to Board of Directors

July 9, 2025 | globenewswire.com

Relmada Therapeutics Inc News (RLMD) - Investing.com

July 2, 2025 | investing.com

RLMD Relmada Therapeutics, Inc. - Seeking Alpha

July 2, 2025 | seekingalpha.com

Relmada Therapeutics' Market Cap Drops To US$22m Leaving Insiders With Losses

June 28, 2025 | uk.finance.yahoo.com

Relmada Therapeutics, Inc. (RLMD) - Yahoo Finance

June 26, 2025 | finance.yahoo.com

RLMD - Relmada Therapeutics Inc Executives - Morningstar

June 24, 2025 | morningstar.comM

Relmada Therapeutics Appoints Dr. Raj S. Pruthi as Chief Medical Officer for Urology to Advance NDV-01 Program for Bladder Cancer

June 17, 2025 | quiverquant.comQ

Relmada Therapeutics Appoints Urology Expert Raj S. Pruthi, MD as CMO-Urology

June 17, 2025 | globenewswire.com

Relmada Therapeutics, Inc. (NASDAQ:RLMD) CFO Purchases $22,000.00 in Stock

May 21, 2025 | insidertrades.com

Relmada Therapeutics, Inc. (NASDAQ:RLMD) Q1 2025 Earnings Call Transcript

May 14, 2025 | msn.com

Relmada Therapeutics, Inc. (RLMD) Q1 2025 Earnings Call Transcript

May 12, 2025 | seekingalpha.com

Relmada Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

May 12, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

RLMD, CRVO, MIST, and IPA Company Descriptions

CervoMed NASDAQ:CRVO

$9.70 +0.30 (+3.20%)

As of 02:14 PM Eastern

CervoMed Inc., a biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. Its lead drug candidate is neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, frontotemporal dementia, and ischemic stroke recovery. The company also develops EIP200 for central nervous system which is in preclinical trials. CervoMed Inc. was founded in 2010 and is headquartered in Boston, Massachusetts.

ImmunoPrecise Antibodies NASDAQ:IPA

$1.98 -0.05 (-2.23%)

As of 02:14 PM Eastern

ImmunoPrecise Antibodies Ltd., together with its subsidiaries, operates as a biotherapeutic research and technology company in Canada and internationally. It provides NonaVac DNA for complex protein classes, including GPCRs and ion channels; and Rapid Prime, a positive monoclonal antibodies for generating anti-idiotypic antibodies, and producing monoclonal antibodies against conformational epitopes. The company also offers syngeneic cell line for immunization and screening; and peptide production for subsequent antibody discovery campaign. In addition, it provides B cell select platform which allows for the interrogation of animal antibody repertoire; screening of the immune repertoire of rabbits and chickens and select the desired antibody directly from the B cells; single step hybridoma, a semi-solid media to grow mouse and rat hybridomas; and DeepDisplay, a combination of transgenic animal platform and custom IPA phage display antibody selection. The company also offers phage display, a custom immune libraries from multiple species; and CAR development, an adaptable antibody which allows the inclusion of functional data early in the screening funnel. Further, it provides silico developability, a profiling toolset for antibody lead candidates; and vitro analytical tools for the study of various critical quality attributes. Additionally, the company offers LucinaTech, an antibody humanization to identify essential framework and CDR residues; antibody affinity maturation for therapeutic and diagnostic application; and antibody chimerization for cloning and production of variable antibody domain. It also provides Eurofins preclinical services; hybrid service model, a service model designed to reduce time and risk with custom technologies and applications; and breadth and depth to accelerate assay development, screening cascades, drug candidate validation, and new biotherapeutic concepts. The company was incorporated in 1983 and is headquartered in Victoria, Canada.

Milestone Pharmaceuticals NASDAQ:MIST

$1.72 +0.06 (+3.31%)

As of 02:14 PM Eastern

Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate. It has a license and collaboration agreement with Ji Xing Pharmaceuticals to develop and commercialize etripamil prophylactic and therapeutic uses in humans, as well as with the Montreal Heart Institute, the WCN network, and other research centers. The company was incorporated in 2003 and is headquartered in Montréal, Canada.

Relmada Therapeutics NASDAQ:RLMD

$0.57 -0.02 (-3.57%)

As of 02:13 PM Eastern

Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system diseases (CNS) and other disorders in the United States. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a N-methyl-D-aspartate receptor antagonist which is in phase 3 clinical trial for the adjunctive or monotherapy treatment of major depressive disorder. The company is headquartered in Coral Gables, Florida.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time